Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion injury in rats

Ito, Kazuhiro; Shimada, Junichi; Kato, Daishiro; Toda, Shogo; Takagi, Tomohisa; Naito, Yuji; Yoshikawa, Toshikazu; Kitamura, Nobuo
April 2004
European Journal of Cardio-Thoracic Surgery;Apr2004, Vol. 25 Issue 4, p530
Academic Journal
Objectives: Lung injury induced by ischemia-reperfusion is the main cause of early graft failure after lung transplantation, which may result from oxygen-free radicals, inflammatory cytokine production, and polymorphonuclear leukocyte accumulation into the interstitium, resulting in severe lung edema. Peroxisome proliferator-activated receptor-γ (PPAR-γ) belongs to the nuclear receptor superfamily and has an anti-inflammatory effect by preventing the activation of transcription factors such as nuclear factor-κB (NF-κB). NF-κB regulates the expression of many genes of early response products in the development of acute inflammation. We examined the effects of pioglitazone, a synthetic ligand of PPAR-γ, against lung ischemia-reperfusion injury in rats. Methods: The left lungs of male Wistar rats were rendered ischemic for 90 min and then reperfused for 2 h. Treated animals received pioglitazone (10 mg/kg) 2 h before induction of ischemia. Lung injury was quantified in terms of lung microvascular permeability (Evans blue dye extravasation), tissue lipid peroxidation (thiobarbituric acid reactive substances), and tissue polymorphonuclear leukocyte accumulation (myeloperoxidase activity). The tissue concentrations of tumor necrosis factor-α (TNF-α) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) were also measured. Statistical analyses were performed by one-way analysis of variance, followed by Sheffe''s multiple comparison test. Results: The lung vascular permeability in pioglitazone-treated animals was reduced by 55% of the increase of Evans blue dye extravasation relative to control animals (P=0.003). The protective effects of pioglitazone treatment were correlated with the reduction by 79% of the increase of thiobarbituric acid reactive substances (P=0.045) and the reduction by 58% of myeloperoxidase activity increase (P<0.001). The production of TNF-α was reduced by 63% of the increase (P<0.001) and the reduction of CINC-1 was 45% (P<0.001). Pioglitazone did not affect the lung in the sham animals. Conclusions: Pioglitazone treatment before ischemia attenuated lung ischemia-reperfusion injury in rats. The mechanism of these protective effects involves inhibition of the production of proinflammatory cytokines, polymorphonuclear leukocyte accumulation, and tissue lipid peroxidation, resulting in reduced lung edema.


Related Articles

  • Peroxisome proliferator-activated receptor-? activation inhibits tumor progression in non-small-cell lung cancer. Keshamouni, Venkateshwar G.; Reddy, Raju C.; Arenberg, Douglas A.; Joel, Binju; Thannickal, Victor J.; Kalemkerian, Gregory P.; Standiford, Theodore J. // Oncogene;1/8/2004, Vol. 23 Issue 1, p100 

    The peroxisome proliferator-activated receptor-gamma (PPAR-?) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and a crucial regulator of cellular differentiation. Differentiation-inducing and antiproliferative effects of PPAR-? suggest that...

  • Therapeutic receptor targets of ischemic preconditioning. Fryer, Ryan M.; Auchampach, John A.; Gross, Garrett J. // Cardiovascular Research;Aug2002, Vol. 55 Issue 3, p520 

    This review focuses on target receptors that have been shown to have the potential to mimic the cardioprotective effect of ischemic preconditioning (IPC). There is an abundance of information concerning the intracellular mechanisms and membrane-bound receptors responsible for IPC. Important...

  • Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Saez, Enrique; Olson, Peter; Evans, Ronald M. // Nature Medicine;Oct2003, Vol. 9 Issue 10, p1265 

    The role of the nuclear peroxisome proliferator-activated receptor (PPAR)-? in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor. We have directly...

  • Endurance Training in Humans Leads to Fiber Type-Specific Increases in Levels of Peroxisome Proliferator-Activated Receptor-α Coactivator-1 and Peroxisome Proliferator-Activated Receptor-α in Skeletal Muscle. Russell, Aaron P.; Feilchenfeldt, Jonas; Meier, Christoph A.; Schreiber, Sylvia; Praz, Manu; Crettenand, Antoinette; Gobelet, Charles; Dériaz, Olivier; Bell, David R.; Kralli, Anastasia; Giacobino, Jean-Paul // Diabetes;Dec2003, Vol. 52 Issue 12, p2874 

    The peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1 (PGC-1) can induce mitochondria biogenesis and has been implicated in the development of oxidative type I muscle fibers. The PPAR isoforms α, β/δ, and γ control the transcription of genes involved in fatty acid...

  • Peroxisome Proliferator-Activated Receptor-γ: Novel Therapeutic Target Linking Adiposity, Insulin Resistance, and Atherosclerosis. Kepez, Alper; Oto, Ali; Dagdelen, Selcuk // BioDrugs;2006, Vol. 20 Issue 2, p121 

    Insulin resistance and obesity is a common health problem in the industrialized world. As a result of the availability of high-calorie food and a reduction in energy expenditure, maladaptive metabolic processes may interfere with the action of insulin and increase susceptibility for the...

  • Agonists of Peroxisome Proliferator-Activated Receptor γ Inhibit Cell Growth in Malignant Melanoma. Mössner, Rotraut; Schulz, Ulrike; Krüger, Ullrich; Middel, Peter; Schinner, Sven; Füzesi, László; Neumann, Christine; Reich, Kristian // Journal of Investigative Dermatology;Sep2002, Vol. 119 Issue 3, p576 

    Peroxisome proliferator-activated receptor γ is a member of the nuclear receptor superfamily involved in adipocyte differentiation and glucose homeostasis. There is evidence that peroxisome proliferator-activated receptor γ may also act as a tumor suppressor. Here, we demonstrate...

  • Cross-Talk between PPARs and the Partners of RXR: A Molecular Perspective. Alan Chan, Lap Shu; Wells, Richard A. // PPAR Research;2009, Special section p1 

    The PPARs are integral parts of the RXR-dependent signaling networks. Many other nuclear receptor subfamily 1 members also require RXR as their obligatory heterodimerization partner and they are often co-expressed in any given tissue. Therefore, the PPARs often complete with other RXR-dependent...

  • New Pharmacological Perspectives and Therapeutic Potential of PPAR-? Agonists. de la Lastra, C. Alarc�n; S�nchez-Fidalgo, S.; Villegas, I.; Motilva, V. // Current Pharmaceutical Design;Nov2004, Vol. 10 Issue 28, p3505 

    The peroxisome proliferator-activated receptor gamma (PPAR?), a member of the nuclear hormone receptor superfamily has classically been characterized for its implications in adipocyte differentiation and fat metabolism. Recently, PPARg has been implicated in the pathophysiology of inflammatory...

  • Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-α (PPARα). Tien, Eric S.; Hannon, Daniel S.; Thompson, Jerry T.; Vanden Heuvel, John P. // PPAR Research;2006, p1 

    The ligand-dependent recruitment of coactivators to peroxisome proliferator-activated receptor-α (PPARα) was examined. PPARbinding protein (PBP), PPARγ coactivator-1α (PGC-1α), steroid receptor coactivator-1 (SRC-1), and CBP/p300-interacting transactivator with ED-rich tail 2...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics